

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF Art Unit: 1647

Jacques BOLLEKENS, et al.

Examiner: SAOUD, CHRISTINE J.

INTERNATIONAL APPLICATION NO: PCT/EP2004/012572

FILED: 5 November 2004

U.S. APPLICATION NO.: 10/578,470

FILED: 18 April 2008

FOR: Use of Fibroblast Growth Factor Fragments

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

RESPONSE TO
OFFICE COMMUNICATION

Sir:

This is in response to the Office Communication mailed 6 May 2011, a response to which is due 6 June 2011. This communication is timely filed.

In response to the Office Communication, we filed a Divisional patent application, Application No. 13/152,750, on 3 June 2011. We will pursue methods of treatment claims in this new Divisional application.

Applicants have not dedicated to the public or abandoned any subject matter. Applicants expressly reserve the right to pursue prosecution of any presently excluded subject matter or claim embodiments in one or more future continuation and/or divisional application(s).

The Commissioner is hereby authorized to charge any fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 50-4409 in the name of Novartis.

Please feel free to contact the below signed person with any issues or questions.

Respectfully submitted,

Novartis Institutes for Biomedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139
(617) 871-5077

/ Frank Wu /
Frank Wu
Agent for Applicants
Reg. No. 41,386

Date: 3 June 2011